Avalo Therapeutics Inc. logo

Avalo Therapeutics Inc. (C6K0)

Market Open
XMUN XMUN
63M Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
Previous Close
Day Range
0 0
Year Range
0 0
Want to track C6K0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

C6K0 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XMUN (EUR).

C6K0 Chart

Similar

Flerie AB
-
-
PUS
Pulsion Medical Systems SE
21.6
0%
37T
Forte Biosciences, Inc.
-
-
4A8
Abeo S.A.
8.72
0%

Avalo Therapeutics Inc. (C6K0) FAQ

What is the stock price today?

The current price is €0.00.

On which exchange is it traded?

Avalo Therapeutics Inc. is listed on XMUN.

What is its stock symbol?

The ticker symbol is C6K0.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 63M.

Has Avalo Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Avalo Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
- CEO
XMUN Exchange
- ISIN
Germany Country
- Employees
- Last Dividend
29 Dec 2023 Last Split
- IPO Date

Overview

Avalo Therapeutics Inc. is heralded as an innovative force within the biopharmaceutical sector, focusing its efforts on the discovery, development, and commercialization of novel treatments aimed at rare and immune-mediated diseases. With a mission centered on fulfilling the unmet medical needs of patients, Avalo commits to pioneering significant clinical advancements. The organization underscores its dedication by targeting particular disease pathways that remain underserved by the broader pharmaceutical industry, placing itself at the forefront of medical research and therapy development. As it navigates the complex landscapes of biotechnology and healthcare, Avalo Therapeutics Inc. stands as a beacon of hope for individuals suffering from conditions that currently lack adequate treatment options.

Products and Services

Avalo Therapeutics Inc. boasts a diversified pipeline of drug candidates, each designed to address specific challenges within its focus areas. Below is an overview of their primary products and services:

  • Drug Candidates for Rare Diseases: Avalo is developing pioneering therapies aimed at rare diseases - a territory often neglected by larger pharmaceutical companies. By focusing on this niche, Avalo ensures that patients with these less common conditions have the hope of finding effective treatments.
  • Immune-Mediated Disease Treatments: Another cornerstone of Avalo's pipeline is its commitment to immune-mediated diseases. Through targeted research and novel drug development, Avalo seeks to interrupt disease pathways effectively, offering new hope to patients with these complex conditions.
  • Innovative Research and Development: At the heart of Avalo's operations lies its innovative R&D efforts. This encompasses the development of new drug molecules and treatment methodologies designed to offer more effective and efficient solutions for the diseases in Avalo’s purview. Avalo’s approach to innovation is not just about creating new drugs but also about improving how these diseases are treated, ensuring that their solutions are groundbreaking and capable of setting new standards in healthcare.

Contact Information

Address: -
Phone: -